GlassScriptPhysician profile
Jonathan S Scharfstein
NPI 1730192360
$3,663.62
in general payments reported to CMS, 2019-2025
18 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $28.46 · 2021: $158 · 2022: $455 · 2023: $2,148 · 2024: $143 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Travel and Lodging: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.04 |
| Travel and Lodging | $1,068.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,385.58 | 2019-2025 | Optis, Mitraclip, Dragonfly Opstar |
| Boston Scientific Corporation | $222.30 | 2022-2025 | Vigilant X4 Crt-D, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.45 | 2022-2025 | Lifevest |
| Alexion Pharmaceuticals, INC. | $136.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $127.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $85.40 | 2021-2022 | |
| Novo Nordisk INC | $80.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $77.47 | 2021-2024 | Eliquis, Camzyos |
| Abiomed | $76.04 | 2019-2023 | Impella |
| Cardiovascular Systems INC. | $74.00 | 2019-2023 | Diamondback Coronary |
| Daiichi Sankyo INC. | $51.33 | 2023-2024 | Injectafer |
| Shockwave Medical, INC | $37.32 | 2021-2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Regeneron Healthcare Solutions, INC. | $28.83 | 2019 | |
| Ekos Corporation | $23.99 | 2019 | |
| Amgen INC. | $23.03 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.67 | 2022 | |
| Elutia, INC. | $15.02 | 2023 | |
| Preventice Services, LLC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Scharfstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.